MX2014013256A - Formulaciones de acido poliinosinico-policitidilico (poli(i:c)) para el tratamiento de infecciones de las vias respiratorias altas. - Google Patents

Formulaciones de acido poliinosinico-policitidilico (poli(i:c)) para el tratamiento de infecciones de las vias respiratorias altas.

Info

Publication number
MX2014013256A
MX2014013256A MX2014013256A MX2014013256A MX2014013256A MX 2014013256 A MX2014013256 A MX 2014013256A MX 2014013256 A MX2014013256 A MX 2014013256A MX 2014013256 A MX2014013256 A MX 2014013256A MX 2014013256 A MX2014013256 A MX 2014013256A
Authority
MX
Mexico
Prior art keywords
poly
upper respiratory
polyinosinic
formulations
treatment
Prior art date
Application number
MX2014013256A
Other languages
English (en)
Inventor
Lieven Elvire Colette Baert
Bruce Albert Malcolm
Roger Paulus Maria Sutmuller
Original Assignee
Janssen R & D Ireland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48430695&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2014013256(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen R & D Ireland filed Critical Janssen R & D Ireland
Publication of MX2014013256A publication Critical patent/MX2014013256A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una composición que comprende micropartículas de ácido poliinosínico-policitidílico (Poli (I:C)) y un polímero portador seleccionado entre almidón, alginato, blanosa o DPPC (dipalmitoilfosfatidilcolina) para su uso en la prevención y/o el tratamiento de infecciones víricas de las vías respiratorias altas o el resfriado común, y un dispositivo, preferentemente un sistema de suministro nasal, que comprende dicha composición para su uso en un paciente que necesita prevenir y/o tratar infecciones o el resfriado común.
MX2014013256A 2012-05-03 2013-05-02 Formulaciones de acido poliinosinico-policitidilico (poli(i:c)) para el tratamiento de infecciones de las vias respiratorias altas. MX2014013256A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12166595 2012-05-03
PCT/EP2013/059079 WO2013164380A1 (en) 2012-05-03 2013-05-02 Polyinosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections

Publications (1)

Publication Number Publication Date
MX2014013256A true MX2014013256A (es) 2015-01-16

Family

ID=48430695

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014013256A MX2014013256A (es) 2012-05-03 2013-05-02 Formulaciones de acido poliinosinico-policitidilico (poli(i:c)) para el tratamiento de infecciones de las vias respiratorias altas.

Country Status (17)

Country Link
US (3) US9682096B2 (es)
EP (1) EP2846767B1 (es)
JP (1) JP6349304B2 (es)
KR (1) KR102240042B1 (es)
CN (1) CN104394846B (es)
AU (1) AU2013255885C1 (es)
BR (1) BR112014026957A8 (es)
CA (1) CA2866230C (es)
CL (1) CL2014002929A1 (es)
CO (1) CO7101247A2 (es)
ES (1) ES2911116T3 (es)
IN (1) IN2014MN02359A (es)
MX (1) MX2014013256A (es)
NZ (1) NZ630040A (es)
RU (1) RU2650636C2 (es)
SG (2) SG11201406208QA (es)
WO (1) WO2013164380A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102240042B1 (ko) 2012-05-03 2021-04-14 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 상기도 감염 치료용 폴리이노신산-폴리사이티딜산(폴리 (i:c)) 제형
JP6629216B2 (ja) * 2013-11-06 2020-01-15 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー 上気道感染症の治療のためのポリイノシン酸−ポリシチジル酸（ポリ（ｉ：ｃ））製剤
GB201415381D0 (en) 2014-08-29 2014-10-15 Algipharma As Inhalable powder formulations of alginate oligomers
WO2016181226A1 (en) * 2015-05-11 2016-11-17 Janssen Sciences Ireland Uc Polyinosinic-polycytidylic acid (poly(i:c)) pea starch formulation for the prevention and/or treatment of upper respiratory tract infections
EP3319587B1 (en) 2015-11-17 2019-08-21 Bioncotech Therapeutics, S.L Novel pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine
CA3006563A1 (en) * 2015-11-30 2017-06-08 Novus Therapeutics, Inc. Compositions and methods for otologic prophylaxis and treatment
CN110177545A (zh) 2016-11-16 2019-08-27 爱尔兰詹森科学公司 用于预防上呼吸道感染的聚肌苷酸和聚胞苷酸的制剂
US10849921B2 (en) 2017-05-17 2020-12-01 Bioncotech Therapeutics Sl Pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine
JP7366434B2 (ja) * 2018-06-29 2023-10-23 信福（北京）医▲薬▼科技有限公司 免疫応答を強化するための複合物

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8723846D0 (en) 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system
US5707644A (en) * 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
EP0535937B2 (en) 1991-10-01 2008-05-21 Takeda Chemical Industries, Ltd. Prolonged release microparticle preparation and production of the same
GB9606188D0 (en) * 1996-03-23 1996-05-29 Danbiosyst Uk Pollysaccharide microspheres for the pulmonary delivery of drugs
MY118835A (en) 1997-04-18 2005-01-31 Ipsen Pharma Biotech Sustained release compositions and the process for their preparation
CA2203843C (en) 1997-04-28 2013-07-23 Her Majesty The Queen, In Right Of Canada, As Represented By The Ministe R Of National Defence Liposome-encapsulated poly iclc
MA25590A1 (fr) * 1998-09-14 2002-12-31 Inhale Therapeutic Syst Agent actif de delivraison de poudre seche
AU9445801A (en) * 2000-10-06 2002-04-15 Bioglan Ab Biodegradable microparticles for controlled release administration, with purified amylopectin-based starch of reduced molecular weight
US20040248837A1 (en) 2002-11-01 2004-12-09 Eyal Raz Methods of treating pulmonary fibrotic disorders
US7638138B2 (en) 2003-02-21 2009-12-29 Translational Research, Ltd. Compositions for nasal administration of pharmaceuticals
CN1867355A (zh) 2003-08-11 2006-11-22 财团法人阪大微生物病研究会 包含诱导粘膜免疫的佐剂的新型疫苗
CA2548992A1 (en) * 2003-12-11 2005-08-11 Vaxdesign Corporation Immunotherapy compositions, method of making and method of use thereof
CN101229378A (zh) 2005-05-05 2008-07-30 国家淀粉及化学投资控股公司 用于送递活性剂的组合物
JP2008542405A (ja) 2005-06-08 2008-11-27 ニューバイオメッド ピーアイケイエイ プライベート リミテッド ポリイノシン酸‐ポリシチジル酸に基づくアジュバント
US20070166239A1 (en) * 2006-01-13 2007-07-19 Haixiang Lin Mucosal immunogenic substances comprising a polyinosinic acid - polycytidilic acid based adjuvant
GB0607534D0 (en) 2006-04-13 2006-05-24 Univ London Pharmacy Colonic drug delivery formulation
CA2658496A1 (en) 2006-07-22 2008-01-31 Oxagen Limited 2-{5-fluoro-2-methyl-3-[2-(phenylsulfonyl)benzyl]-1h-indol-yl} acetic acid derivatives and esters thereof having crth2 antagonist activity
CL2007002218A1 (es) 2006-08-03 2008-03-14 Celgene Corp Soc Organizada Ba Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
AR067997A1 (es) 2007-08-24 2009-10-28 Novartis Ag Compuestos organicos
JP2009209086A (ja) * 2008-03-04 2009-09-17 Masami Moriyama 粘膜投与型ワクチン
UA90013C2 (ru) * 2008-03-19 2010-03-25 Давид Анатолійович Нога Фармацевтическая композиция, содержащая инсулин, и способ его получения
EP2116602A1 (en) 2008-05-07 2009-11-11 Institut Gustave Roussy Combination products for treating cancer
US9498431B2 (en) * 2008-12-10 2016-11-22 Jianjian Xu Controlled releasing composition
CN101491503A (zh) 2008-12-17 2009-07-29 天津瑞普生物技术股份有限公司 一种用于宠物的聚肌胞滴丸及其制备方法
US9006406B2 (en) 2008-12-22 2015-04-14 Alexander Levitzki EGFR-homing double-stranded RNA vector for systemic cancer treatment
CN101757018A (zh) * 2008-12-24 2010-06-30 天津瑞普生物技术股份有限公司 一种用于畜禽的聚肌胞干粉及其制备方法
WO2010114169A1 (en) 2009-03-31 2010-10-07 Japan As Represented By The Director-General Of National Institute Of Infectious Diseases Method for prophylaxis of influenza using vaccine for intranasal administration
JP2013535457A (ja) 2010-07-28 2013-09-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器系及び炎症性疾患の治療用医薬組成物
US8431155B1 (en) 2012-04-30 2013-04-30 Veroscience Llc Bromocriptine formulations
KR102240042B1 (ko) 2012-05-03 2021-04-14 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 상기도 감염 치료용 폴리이노신산-폴리사이티딜산(폴리 (i:c)) 제형
JP6629216B2 (ja) 2013-11-06 2020-01-15 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー 上気道感染症の治療のためのポリイノシン酸−ポリシチジル酸（ポリ（ｉ：ｃ））製剤

Also Published As

Publication number Publication date
NZ630040A (en) 2016-10-28
US9682096B2 (en) 2017-06-20
RU2014148544A (ru) 2016-06-27
KR102240042B1 (ko) 2021-04-14
SG11201406208QA (en) 2014-11-27
US20160296551A1 (en) 2016-10-13
KR20150008855A (ko) 2015-01-23
JP6349304B2 (ja) 2018-06-27
BR112014026957A8 (pt) 2018-01-16
AU2013255885B2 (en) 2017-10-05
CO7101247A2 (es) 2014-10-31
BR112014026957A2 (pt) 2017-06-27
CN104394846A (zh) 2015-03-04
SG10201607288VA (en) 2016-10-28
CA2866230C (en) 2020-08-18
EP2846767A1 (en) 2015-03-18
AU2013255885C1 (en) 2018-04-26
CA2866230A1 (en) 2013-11-07
AU2013255885A1 (en) 2014-09-25
JP2015515968A (ja) 2015-06-04
ES2911116T3 (es) 2022-05-17
US20180325939A1 (en) 2018-11-15
WO2013164380A1 (en) 2013-11-07
IN2014MN02359A (es) 2015-08-14
RU2650636C2 (ru) 2018-04-16
CN104394846B (zh) 2018-10-19
US10485816B2 (en) 2019-11-26
US9987300B2 (en) 2018-06-05
EP2846767B1 (en) 2022-01-26
CL2014002929A1 (es) 2015-01-16
US20150140042A1 (en) 2015-05-21
HK1203390A1 (en) 2015-10-30

Similar Documents

Publication Publication Date Title
MX2014013256A (es) Formulaciones de acido poliinosinico-policitidilico (poli(i:c)) para el tratamiento de infecciones de las vias respiratorias altas.
MX2016005883A (es) Formulaciones de acido poliinosinico-policitidilico (poli (i:c))para el tratamiento de infecciones del tracto respiratorio superior.
WO2016086088A3 (en) Wound healing through sirt1 overexpression
SG10201804552WA (en) Nanoparticle compositions, formulations thereof, and uses therefor
MX2013005294A (es) Composicion que comprende un agonista de receptor de serotonina y una dicetopiperazina para el tratamiento de migrañas.
TN2014000345A1 (en) Pharmaceutical preparation containing an antivirally active dihydroquinazoline derivative
BR112014032699A2 (pt) métodos de tratamento de síndrome metabólica pediátrica
MY166557A (en) Quinazoline derivatives for the treatment of viral infections and further diseases
WO2009059371A3 (en) Systems, methods and devices for circulatory access
MX369385B (es) Productos para cicatrizar heridas tisulares.
EA201390409A1 (ru) Составы с низкой дозой панкрелипазы и кишечно-растворимым покрытием
WO2008154482A3 (en) Sirna compositions and methods of use in treatment of ocular diseases
PH12015500713B1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
IN2015DN03219A (es)
MX352824B (es) Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado común e inflamación.
MX365688B (es) Sistemas de administracion de farmaco y metodos para el tratamiento del cancer de vejiga que comprenden oxaliplatino.
EP3300734A3 (en) Use of levocetirizine and montelukast in the treatment of autoimmune disorders
WO2014184576A3 (en) Delivery of a therapeutic agent to the cerebral cortex by administering a viral vector by convection enhanced diffusion into the white matter of the brain
MY193694A (en) Membrane-adherent self-assembled systems for treatment of ocular disorders
WO2014164285A3 (en) Use of levocetirizine and montelukast in the treatment of vasculitis
MX341220B (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de infecciones microbianas.
BR112014021497A2 (pt) sistema de entrega de fármaco baseado em jcv-vlp
WO2011163512A3 (en) Cancer therapy
WO2013181217A3 (en) Novel compounds and compositions for treatment of breathing control disorders or diseases
EA201591095A1 (ru) Белок slurp-1 для применения в лечении глазных болезней